In which industries is Johnson & Johnson primarily active?

Johnson & Johnson is primarily active in the healthcare industry. With a diverse range of products, the company operates in multiple sectors such as pharmaceuticals, medical devices, and consumer health. Johnson & Johnson is renowned for its comprehensive portfolio that includes prescription drugs, over-the-counter medications, surgical equipment, contact lenses, and personal care products. Being a global leader, Johnson & Johnson's presence extends across various healthcare segments, enabling it to contribute significantly to advancing medical solutions and enhancing overall well-being.

Who are the main competitors of Johnson & Johnson in the market?

Some of the main competitors of Johnson & Johnson in the market include Pfizer Inc., Merck & Co., Inc., and Roche Holding AG.

What is the history and background of the company Johnson & Johnson?

Johnson & Johnson is a multinational healthcare company that was founded in 1886. It has a rich history and has become a leader in the pharmaceutical, medical devices, and consumer healthcare sectors. With over 130 years of experience, Johnson & Johnson has continually focused on delivering innovative solutions to improve the health and well-being of people around the world. The company has grown through strategic acquisitions and partnerships, expanding its product portfolio and global presence. Johnson & Johnson's commitment to research and development, along with its dedication to ethical business practices, have made it a trusted name in the healthcare industry.

What significant milestones has the company Johnson & Johnson achieved?

Some significant milestones achieved by Johnson & Johnson include the development of innovative medical treatments and breakthrough pharmaceutical products. Throughout its history, the company has also played a crucial role in the advancement of healthcare technology and the improvement of patient care. Johnson & Johnson has consistently demonstrated its commitment to quality and safety, earning a reputation as a trusted global healthcare leader. With a strong focus on research and development, the company has introduced numerous life-saving and life-enhancing solutions to address a wide range of medical needs. Through its dedication to innovation and excellence, Johnson & Johnson continues to shape the future of healthcare.

In which countries and regions is Johnson & Johnson primarily present?

Johnson & Johnson is primarily present in several countries and regions worldwide. The company has a significant presence in the United States, where it is headquartered, and it operates in countries across North America, Europe, Asia Pacific, and Latin America. Some prominent regions where Johnson & Johnson operates include Canada, Germany, France, Japan, Australia, Brazil, and China. With its diverse portfolio of healthcare products and services, Johnson & Johnson continues to expand its presence globally, serving the healthcare needs of people in numerous countries and regions.

What values and corporate philosophy does Johnson & Johnson represent?

Johnson & Johnson is a renowned global healthcare company that upholds strong values and a clear corporate philosophy. With a commitment to improving the well-being of people worldwide, the company focuses on three fundamental principles: caring for the world, keeping customers at the center, and cherishing employees. Johnson & Johnson values integrity, innovation, diversity, and collaboration, consistently striving to deliver high-quality products and solutions. With a customer-centric approach, the company endeavors to create lasting relationships and enhance experiences. By fostering a supportive work environment and promoting professional growth, Johnson & Johnson ensures its employees play a vital role in achieving its mission.

What is the business model of Johnson & Johnson?

Johnson & Johnson is one of the largest healthcare companies in the world. The company was founded in 1886 and is based in New Brunswick, New Jersey. With a wide portfolio of products and services, Johnson & Johnson is active in the consumer goods, medical technology, and pharmaceutical sectors. Consumer Goods: Johnson & Johnson is best known for its baby care products, such as diapers and wipes. The company also offers a wide range of other products, including personal care, wound healing, and pain relief products. Medical Technology: As a global leader in medical devices and instruments, Johnson & Johnson provides solutions for various areas of the medical field. In orthopedics, for example, the company offers implants for a variety of joints and bones. In medical imaging, Johnson & Johnson has a diverse range of devices that can be used for diagnosis and treatment. Pharmaceuticals: Johnson & Johnson is also active in the pharmaceutical business. The company is a global leader in the development and marketing of prescription drugs. In the field of oncology, for example, Johnson & Johnson offers various medications for the treatment of cancer. The company is also involved in neurology and immunology, offering a wide range of medications. Innovative Technologies: Johnson & Johnson heavily invests in innovative technologies to improve treatment options for patients. Examples of this include the "CaringCrowd" crowdfunding platform and the "Janssen Health EMEA Innovation Center," a platform for start-ups and companies focusing on groundbreaking innovations in healthcare. Research and Development: Research and development is a crucial aspect of Johnson & Johnson's business success. The company invests significant amounts each year in the research and development of new products and technologies. The goal is to develop products that meet the needs of patients and address various diseases and conditions. Johnson & Johnson also conducts extensive clinical studies to ensure the safety and efficacy of its products. Conclusion: Johnson & Johnson has a diverse range of products and services. The company is a leading provider in consumer goods, medical technology, and pharmaceuticals. It heavily invests in innovative technologies and research and development to offer treatment options to patients worldwide that meet the highest standards in terms of efficacy and safety. The output answer: Johnson & Johnson is a global healthcare company that offers a wide range of consumer goods, medical technology, and pharmaceutical products. It invests in innovative technologies and research and development to provide effective and safe treatment options for patients worldwide.

What is the revenue of Johnson & Johnson 2026?

The expected revenue of Johnson & Johnson is 101.54 B USD. This figure is based on current financial data and reflects the company's business performance.

How high is the profit of Johnson & Johnson 2026?

The expected profit of Johnson & Johnson is 28.3 B USD. The net profit reflects the company's profitability after deducting all expenses.

What is the P/E ratio of Johnson & Johnson 2026?

The price-to-earnings ratio (P/E) of Johnson & Johnson is currently 20.01. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Johnson & Johnson stock.

What is the P/S ratio of Johnson & Johnson 2026?

The price-to-sales ratio (P/S) of Johnson & Johnson is currently 5.58. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Johnson & Johnson stock.

What is the Eulerpool Quality Score of Johnson & Johnson?

The Eulerpool Quality Score for Johnson & Johnson is 6/10.

What is the Johnson & Johnson ISIN?

The ISIN of Johnson & Johnson is US4781601046. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

What is the Johnson & Johnson WKN?

The WKN of Johnson & Johnson is 853260. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

What is the Johnson & Johnson ticker?

The ticker of Johnson & Johnson is JNJ. The ticker symbol is used to trade Johnson & Johnson shares on the stock exchange.

How much dividend does Johnson & Johnson pay?

Over the past 12 months, Johnson & Johnson paid a dividend of 5.14 USD . This corresponds to a dividend yield of about 2.2 %. For the coming 12 months, Johnson & Johnson is expected to pay a dividend of 7.93 USD.

What is the dividend yield of Johnson & Johnson?

The current dividend yield of Johnson & Johnson is 2.2 %.

When does Johnson & Johnson pay dividends?

Johnson & Johnson pays a dividend, distributed in the months of , , , .

How secure is the dividend of Johnson & Johnson?

Johnson & Johnson paid dividends every year for the past 62 years.

What is the dividend of Johnson & Johnson?

For the upcoming 12 months, dividends amounting to 7.93 USD are expected. This corresponds to a dividend yield of 3.4 %.

In which sector is Johnson & Johnson located?

Johnson & Johnson is assigned to the 'Health' sector.

When did I have to buy Johnson & Johnson shares to receive the previous dividend?

To receive the latest dividend of Johnson & Johnson from amounting to 1.3 USD, you needed to have the stock in your portfolio before the ex-date on .

When did Johnson & Johnson pay the last dividend?

The last dividend was paid out on .

What was the dividend of Johnson & Johnson in the year 2025?

In the year 2025, Johnson & Johnson distributed 4.91 USD as dividends.

In which currency does Johnson & Johnson pay out the dividend?

The dividends of Johnson & Johnson are distributed in USD.

Start Free Trial

Johnson & Johnson (JNJ) Stock Price

Currency:

Johnson & Johnson Price

🇺🇸NYSE·CLOSED

233.15USD

Market closed

Today +/-

Today %

Johnson & Johnson (JNJ) Stock | ISIN US4781601046 | WKN 853260. The current Johnson & Johnson stock price is 233.15 USD (2026). Revenue is 101.54 B USD. Net income is 28.3 B USD. The P/E ratio is 20.01. Market capitalization is 566.4 B USD. Johnson & Johnson operates in the Health sector.

Over the last 19 years Johnson & Johnson grew revenue by 3% annually, reaching 94.19 B USD. Earnings per share have grown at 5.9% per year over the last 19 years. For Johnson & Johnson, the net margin of 28.5% is up versus 26.5% a few years ago. At today's price the dividend yield works out to roughly 2.2%. The payout ratio is around 64% of earnings. The dividend has grown at 6.9% per year over the past 19 years.

Johnson & Johnson stock price

Ex-Dividend

Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Johnson & Johnson over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Johnson & Johnson stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Johnson & Johnson's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Johnson & Johnson Stock Price History

Date	Johnson & Johnson Price

Access this data via the Eulerpool API

Docs Get Free API Key

Johnson & Johnson Revenue, EBIT, Net Income

3 Years
5 Years
10 Years
25 Years
Max

Revenue

EBIT

Net Income

Details

Johnson & Johnson Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jun 17, 2026, 5:59 AM

REVENUE (B USD)

REVENUE GROWTH (%)

GROSS MARGIN (%)

GROSS INCOME (B USD)

NET INCOME (B USD)

NET INCOME GROWTH (%)

DIVIDEND (USD)DIV. (USD)

DIVIDEND GROWTH (%)DIV. GROWTH (%)

SHARES (B)

DOCUMENTS

2024	2025	2026e	2027e	2028e	2029e	2030e	2031e
88.82	94.19	101.54	107.22	113.27	119.89	126.86	128.4
4.3	6.05	7.8	5.6	5.64	5.85	5.82	1.22
69.11	67.88	62.97	59.63	56.45	53.33	50.4	49.79
61.39	63.94	63.94	63.94	63.94	63.94	63.94	63.94
14.07	26.8	28.3	30.72	33.42	36.31	39.91	41.23
-59.99	90.56	5.59	8.53	8.79	8.65	9.93	3.3
4.91	5.14	1.3	7.93	8.69	-	-	-
4.47	4.68	-74.71	510	9.58	–	–	–
2.43	2.43	2.43	2.43	2.43	2.43	2.43	2.43
–	–	–	–	–	–	–	–

Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Johnson & Johnson generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Johnson & Johnson retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Johnson & Johnson's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Johnson & Johnson has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Johnson & Johnson's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Johnson & Johnson stock margins

The Johnson & Johnson margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Johnson & Johnson. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Johnson & Johnson.

3 Years
5 Years
10 Years
25 Years
Max

Gross margin

EBIT margin

Profit margin

Details

Johnson & Johnson Stock Revenue, EBIT, Earnings per Share

The Johnson & Johnson earnings per share therefore indicates how much revenue Johnson & Johnson has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

3 Years
5 Years
10 Years
25 Years
Max

Revenue per Share

EBIT per share

Earnings per Share

Details

Johnson & Johnson business model & stock analysis

Johnson & Johnson is an American company that was founded in 1886 by the brothers Robert, James, and Edward Johnson. The company is headquartered in New Brunswick, New Jersey, USA and is now an internationally operating company with more than 130,000 employees worldwide. The history of Johnson & Johnson began with the production of medical bandages. In 1887, the first self-adhesive wound plaster was invented and patented. In the following years, the product range was significantly expanded and now includes a wide range of health products. This includes pharmaceuticals, medical devices, hygiene products, personal care products, and baby products. The business model of Johnson & Johnson is to improve the lives of people worldwide. The company places great importance on innovation, quality, and sustainability. With its long-standing experience and expertise in the healthcare industry, Johnson & Johnson is able to understand the needs of customers and offer products tailored to their specific needs. Johnson & Johnson is now active in three main business areas: Consumer Health, Medical Devices and Diagnostics, and Pharmaceuticals. Within these business areas, there are a variety of brands and products that are among the most well-known in the world. The Consumer Health division of Johnson & Johnson is focused on the production of health and personal care products for consumers. Some well-known brands in this area include Listerine, Johnson's Baby, Neutrogena, and Nicorette. The company offers a wide range of products, from cold and allergy medications to skincare products and toothpastes. Medical Devices and Diagnostics is another major business area of Johnson & Johnson. The company is a leading provider of medical devices and diagnostic products worldwide. Products in this area include surgical systems, implantable devices, diagnostic tests, and imaging devices. Well-known brands in this area include Ethicon, Depuy Synthes, and Cordis. Pharmaceuticals is the third major business area of Johnson & Johnson. The company develops and produces innovative pharmaceuticals for the treatment of diseases such as cancer, diabetes, heart disease, and neurological disorders. Some well-known brands in this area include Remicade, Invega, and Zytiga. Johnson & Johnson is also known for its commitment to sustainability and corporate social responsibility. The company is committed to having a positive impact on the environment and the communities in which it operates. For example, Johnson & Johnson aims to reduce its CO2 emissions by 60% by 2030. Overall, Johnson & Johnson is a leading healthcare company focused on providing innovative and high-quality products that improve the lives of people worldwide. With a wide range of brands and products in various business areas, the company is well positioned to continue to be successful in the future.

Johnson & Johnson SWOT Analysis

Strengths

Johnson & Johnson (J&J) possesses several key strengths that contribute to its success in the market. Firstly, the company has a diversified product portfolio spanning various sectors such as healthcare, pharmaceuticals, and consumer goods. This diversification allows J&J to leverage its brand equity and penetrate multiple markets effectively.

Secondly, J&J has a strong brand reputation built on trust and reliability. The company is known for its high-quality products, which have earned consumer loyalty over the years. This positive brand perception gives J&J a competitive edge and enhances customer trust, leading to continued business growth.

Additionally, J&J has a vast global presence, operating in multiple countries around the world. This global reach provides the company with access to diverse markets and a broad customer base. It enables J&J to adapt to changing market dynamics and explore new growth opportunities.

Weaknesses

Despite its strengths, J&J also faces some notable weaknesses. One of the main weaknesses is its dependence on external suppliers for raw materials and components. Any disruption in the supply chain could impact production and result in delays or shortages of J&J products.

Furthermore, J&J has experienced product recalls and legal issues in the past, which have affected its reputation and financial performance. These incidents highlight a need for stricter quality control measures and regulatory compliance within the organization.

Opportunities

J&J has several opportunities to capitalize on in the market. One notable opportunity is the growing demand for healthcare and pharmaceutical products, driven by an aging population and increasing healthcare needs globally. J&J can leverage its expertise and expand its product offerings to cater to these emerging market needs.

Additionally, advancements in technology and digitalization present opportunities for J&J to enhance its product innovation and delivery channels. Embracing digital platforms and integrating technology in its operations can help the company stay competitive and meet changing customer preferences.

Threats

J&J needs to be aware of several potential threats that may impact its business. One significant threat is increasing competition from both established players and new entrants in the healthcare and pharmaceutical industries. This competition may affect market share and profitability.

Moreover, evolving regulations and policies in the healthcare sector pose a threat to J&J's operations. Compliance with stricter regulations can increase costs and restrict product development and distribution processes.

Additionally, the current global economic environment and geopolitical uncertainties may impact consumer spending patterns, which could result in lower demand for J&J products.

Johnson & Johnson Segments

Johnson & Johnson Revenue by Segment (1/6)

3 Years
5 Years
Max

DARZALEX

Stelara

OTC

ELECTROPHYSIOLOGY

GENERAL

Tremfya

ADVANCED

Remicade

Skin health/Beauty

CONTACT LENSES/OTHER

INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA

ERLEADA

IMBRUVICA

SPINE & OTHER

TRAUMA

SPINE,SPORTS & OTHER

ZYTIGA

Simponi/Simponi Aria

XARELTO

OPSUMIT

PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA

UPTRAVI

CARVYKTI

Abiomed

SPRAVATO

Baby Care

HIPS

OTHER NEUROSCIENCE

KNEES

SURGICAL

Oral Care

EDURANT/rilpivirine

Other

Shockwave Medical, Inc

Women's Health

PROCRIT/EPREX

VELCADE

Other Oncology

INVOKANA/INVOKAMET

RYBREVANT/LAZCLUZE

Wound Care and Other

CAPLYTA

CONCERTA/Methylphenidate

RISPERDAL CONSTA

TECVAYLI

ZYTIGA/abiraterone acetate

TALVEY

Other Infectious Diseases

other cardiovascular

Johnson & Johnson Revenue by Segment (2/6)

3 Years
5 Years
Max

Xarelto

Details

Johnson & Johnson Revenue by Segment (3/6)

3 Years
5 Years
Max

DARZALEX

Stelara

OTC

GENERAL

Tremfya

Beauty

ADVANCED

Remicade

CONTACT LENSES/OTHER

INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA

IMBRUVICA

SPINE & OTHER

TRAUMA

ZYTIGA

Simponi/Simponi Aria

OPSUMIT

PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA

UPTRAVI

Baby Care

HIPS

OTHER NEUROSCIENCE

KNEES

SURGICAL

Oral Care

EDURANT/rilpivirine

Other

Women's Health

SPECIALTY

PROCRIT/EPREX

VELCADE

Other Oncology

INVOKANA/INVOKAMET

Wound Care and Other

CONCERTA/Methylphenidate

RISPERDAL CONSTA

Tremfaya

Other Infectious Diseases

TRACLEER

Other Immunology

Details

Johnson & Johnson Revenue by Segment (4/6)

Innovative Medicine

MedTech

Details

Johnson & Johnson Revenue by Segment (5/6)

3 Years
5 Years
Max

Pharmaceutical

Medical Devices

Consumer

Details

Johnson & Johnson Revenue by Segment (6/6)

3 Years
5 Years
Max

Pharmaceutical

MedTech

Medical Devices

Consumer Health

Consumer

Details

Johnson & Johnson Revenue by Region

3 Years
5 Years
10 Years
Max

Operating Segments

United States

U.S. Plans

Other Countries

Europe

Asia-Pacific, Africa

Western Hemisphere, excluding U.S.

Western Hemisphere excluding U.S

Details

Johnson & Johnson Eulerpool Fair Value

Johnson & Johnson historical P/E ratio, EBIT multiple, and P/S ratio

Johnson & Johnson annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Johnson & Johnson shares outstanding

The number of shares was Johnson & Johnson in 2025 — This indicates how many shares 2.429 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

3 Years
5 Years
10 Years
25 Years
Max

Number of stocks

Details

Johnson & Johnson Dividend History

37 years of dividend payments · 23 consecutive increases

YearAnnual DividendYoY ChangePayments

20261.3USDYTD—1×

Feb 24, 20261.3USD 0.0%1/1

20255.14USD↑ 4.7%4×

Feb 18, 20251.24USD 0.0%1/4

May 27, 20251.3USD↑ 4.8%2/4

Aug 26, 20251.3USD 0.0%3/4

Nov 25, 20251.3USD 0.0%4/4

20244.91USD↑ 4.5%4×

20234.7USD↑ 5.6%4×

20224.45USD↑ 6.2%4×

20214.19USD↑ 5.3%4×

20203.98USD↑ 6.1%4×

20193.75USD↑ 5.9%4×

20183.54USD↑ 6.6%4×

20173.32USD↑ 5.4%4×

Johnson & Johnson dividend history and estimates

In 2025, Johnson & Johnson paid a dividend amounting to 5.14 USD. Dividend means that Johnson & Johnson distributes a portion of its profits to its owners.

3 Years
5 Years
10 Years
25 Years
Max

Dividend

Dividend (Estimate)

Details

Johnson & Johnson dividend payout ratio

In 2025, Johnson & Johnson had a payout ratio of 63.83%. The payout ratio indicates the percentage of the company's profits that Johnson & Johnson distributes as dividends.

3 Years
5 Years
10 Years
25 Years
Max

Payout ratio

Details

Price targets and forecasts for Johnson & Johnson are not yet available.

Johnson & Johnson Earnings Calls

2025

Oct 14Q3 2025 Earnings Call Transcript

PDF Audio

Jul 16Q2 2025 Earnings Call Transcript

PDF Audio

Apr 15Q1 2025 Earnings Call Transcript

PDF Audio

Jan 22Q4 2024 Earnings Call Transcript

PDF Audio

2024

Oct 15Q3 2024 Earnings Call Transcript

PDF Audio

Jul 17Q2 2024 Earnings Call Transcript

PDF Audio

Apr 16Q1 2024 Earnings Call Transcript

PDF Audio

Johnson & Johnson Earnings Estimates

Date	EPS estimate	Revenue Estimate	Quarterly report
4/14/2026	2.7USD	23.86 BUSD	2026 Q1
1/21/2026	2.46USD	24.4 BUSD	2025 Q4
4/16/2024	2.66USD	21.38 BUSD	2024 Q1
1/23/2024	2.45USD	21.21 BUSD	2023 Q4
1/22/2024	2.69USD	25.27 BUSD	2023 Q4
7/17/2023	2.62USD	24.71 BUSD	2023 Q2
4/17/2023	2.6USD	24.12 BUSD	2023 Q1
1/24/2023	2.25USD	24.27 BUSD	2022 Q4
10/18/2022	2.5USD	23.69 BUSD	2022 Q3
7/19/2022	2.56USD	24.13 BUSD	2022 Q2
4/19/2022	2.59USD	23.96 BUSD	2022 Q1
1/25/2022	2.14USD	25.66 BUSD	2021 Q4
10/19/2021	2.37USD	24.07 BUSD	2021 Q3
7/21/2021	2.29USD	22.54 BUSD	2021 Q2
4/20/2021	2.36USD	22.31 BUSD	2021 Q1
1/26/2021	1.84USD	21.99 BUSD	2020 Q4
10/13/2020	2USD	20.5 BUSD	2020 Q3
7/16/2020	1.51USD	17.87 BUSD	2020 Q2
4/14/2020	2.02USD	19.77 BUSD	2020 Q1
1/22/2020	1.89USD	21.12 BUSD	2019 Q4
10/15/2019	2.03USD	20.37 BUSD	2019 Q3
7/16/2019	2.48USD	20.6 BUSD	2019 Q2
4/16/2019	2.06USD	19.9 BUSD	2019 Q1
1/22/2019	1.97USD	20.5 BUSD	2018 Q4
10/16/2018	2.05USD	20.35 BUSD	2018 Q3
7/17/2018	2.09USD	20.7 BUSD	2018 Q2
4/17/2018	2.04USD	19.75 BUSD	2018 Q1
1/23/2018	1.74USD	20.37 BUSD	2017 Q4
10/17/2017	1.82USD	19.57 BUSD	2017 Q3
7/18/2017	1.81USD	19.23 BUSD	2017 Q2
4/18/2017	1.79USD	18.31 BUSD	2017 Q1
1/24/2017	1.58USD	18.55 BUSD	2016 Q4
10/18/2016	1.67USD	18.01 BUSD	2016 Q3
7/19/2016	1.7USD	18.25 BUSD	2016 Q2
4/19/2016	1.66USD	17.74 BUSD	2016 Q1
1/26/2016	1.43USD	18.15 BUSD	2015 Q4
10/13/2015	1.47USD	17.71 BUSD	2015 Q3
7/14/2015	1.69USD	18.02 BUSD	2015 Q2
4/14/2015	1.56USD	17.57 BUSD	2015 Q1
1/20/2015	1.27USD	18.83 BUSD	2014 Q4
10/14/2014	1.46USD	18.65 BUSD	2014 Q3
7/15/2014	1.56USD	19.28 BUSD	2014 Q2
4/15/2014	1.49USD	18.27 BUSD	2014 Q1
1/21/2014	1.21USD	18.22 BUSD	2013 Q4
10/15/2013	1.34USD	17.71 BUSD	2013 Q3
7/16/2013	1.41USD	17.98 BUSD	2013 Q2
4/16/2013	1.41USD	17.68 BUSD	2013 Q1
1/22/2013	1.18USD	17.93 BUSD	2012 Q4
10/16/2012	1.22USD	17.23 BUSD	2012 Q3
7/17/2012	1.3USD	16.94 BUSD	2012 Q2
4/17/2012	1.37USD	16.5 BUSD	2012 Q1
1/24/2012	1.1USD	16.52 BUSD	2011 Q4
10/18/2011	1.22USD	16.26 BUSD	2011 Q3
7/19/2011	1.25USD	16.48 BUSD	2011 Q2
4/19/2011	1.27USD	16.11 BUSD	2011 Q1
1/25/2011	1.04USD	16.27 BUSD	2010 Q4
10/19/2010	1.16USD	15.42 BUSD	2010 Q3
7/20/2010	1.22USD	15.87 BUSD	2010 Q2
4/20/2010	1.29USD	15.84 BUSD	2010 Q1
1/26/2010	0.98USD	15.94 BUSD	2009 Q4
10/13/2009	1.14USD	15.44 BUSD	2009 Q3
7/14/2009	1.13USD	15.25 BUSD	2009 Q2
4/14/2009	1.23USD	15.66 BUSD	2009 Q1
1/20/2009	0.93USD	16.17 BUSD	2008 Q4
10/14/2008	1.12USD	15.93 BUSD	2008 Q3
7/15/2008	1.13USD	16.24 BUSD	2008 Q2
4/15/2008	1.22USD	16.07 BUSD	2008 Q1
1/22/2008	0.87USD	15.63 BUSD	2007 Q4
10/16/2007	1USD	15.06 BUSD	2007 Q3
7/17/2007	1.01USD	15.29 BUSD	2007 Q2
4/17/2007	1.06USD	14.66 BUSD	2007 Q1
1/23/2007	0.8USD	13.88 BUSD	2006 Q4
10/17/2006	0.94USD	13.27 BUSD	2006 Q3
7/18/2006	0.98USD	13.5 BUSD	2006 Q2
4/18/2006	0.99USD	13.41 BUSD	2006 Q1
1/24/2006	0.73USD	13.39 BUSD	2005 Q4
10/18/2005	0.87USD	12.69 BUSD	2005 Q3
7/19/2005	0.92USD	12.77 BUSD	2005 Q2
4/19/2005	0.93USD	12.69 BUSD	2005 Q1
1/25/2005	0.65USD	12.21 BUSD	2004 Q4
10/12/2004	0.77USD	11.47 BUSD	2004 Q3
7/13/2004	0.8USD	11.66 BUSD	2004 Q2
4/13/2004	0.8USD	11.51 BUSD	2004 Q1
1/20/2004	0.57USD	11.05 BUSD	2003 Q4
10/14/2003	0.69USD	10.46 BUSD	2003 Q3
7/15/2003	0.7USD	10.34 BUSD	2003 Q2
4/15/2003	0.68USD	9.77 BUSD	2003 Q1
1/21/2003	0.48USD	9.3 BUSD	2002 Q4
10/15/2002	0.6USD	9.12 BUSD	2002 Q3
7/16/2002	0.59USD	9.02 BUSD	2002 Q2
4/16/2002	0.58USD	8.9 BUSD	2002 Q1

...

EESG©

Eulerpool ESG Scorecard© for the Johnson & Johnson stock

81/100

Environment

Social

Governance

Environment

Scope 1 - Direct Emissions320,104

Scope 2 - Indirect emissions from purchased energy467,934

Scope 3 - Indirect emissions within the value chain6,865,589

Total CO₂ emissions788,038

CO₂ reduction strategy

Coal energy

Nuclear power

Animal experiments

Fur & Leather

Pesticides—

Palm Oil

Tobacco

Genetically modified organisms

Climate concept—

Sustainable forestry—

Recycling regulations

Environmentally friendly packaging

Hazardous substances

Fuel consumption and efficiency

Water consumption and efficiency

Social

Percentage of female employees50.36

Percentage of women in management—

Percentage of Asian employees16.2

Share of Asian management19.8

Percentage of Hispanic/Latino employees9.9

Hispano/Latino Management share8

Percentage of Black employees7.5

Black Management Share6.4

Percentage of white employees63.8

White Management Share63.4

Adult content

Alcohol

Weapons—

Firearms

Gambling

Military contracts

Human rights concept

Privacy concept—

Occupational health and safety

Catholic

Governance (Corporate Governance)

Environmental reporting

Stakeholder Engagement

Call Back Policies

Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Johnson & Johnson shareholder structure

%	Name	Stocks	Change	Date
9.71537%	The Vanguard Group, Inc.	236,025,080	+3,042,763	6/30/2025
5.46626%	State Street Investment Management (US)	132,797,335	-992,450	6/30/2025
5.34138%	BlackRock Institutional Trust Company, N.A.	129,763,575	+619,119	6/30/2025
2.49483%	Geode Capital Management, L.L.C.	60,609,476	+1,225,676	6/30/2025
1.51113%	JP Morgan Asset Management	36,711,385	+1,457,185	6/30/2025
1.41479%	State Farm Insurance Companies	34,371,021		6/30/2025
1.31428%	Norges Bank Investment Management (NBIM)	31,929,124	+1,573,452	6/30/2025
1.04139%	Morgan Stanley Smith Barney LLC	25,299,433	+1,234,167	6/30/2025
1.02398%	Wellington Management Company, LLP	24,876,538	+2,230,577	6/30/2025
0.8169%	BlackRock Asset Management Ireland Limited	19,845,848	+148,418	6/30/2025

...

Johnson & Johnson Executives and Management Board

Mr. Joaquin Duato

(62)

Chairman of the Board, Chief Executive Officer · since 2016

Compensation24.3 MUSD

Compensation24.3 M USD

Mr. Joseph Wolk

(58)

Chief Financial Officer, Executive Vice President

12.62 MUSD

Compensation12.62 M USD

Mr. Tim Schmid

(55)

Executive Vice President, Worldwide Chairman of MedTech

11.86 MUSD

Compensation11.86 M USD

Ms. Jennifer Taubert

(61)

Executive Vice President, Worldwide Chairman, Innovative Medicine

11.19 MUSD

Compensation11.19 M USD

Prof. Dr. John Reed

(66)

Executive Vice President - Innovative Medicine, Research and Development

9.3 MUSD

Compensation9.3 M USD

Johnson & Johnson Supply Chain

Frequently asked questions about Johnson & Johnson

Johnson & Johnson operates under a diversified business model. The company is engaged in the development, manufacturing, and marketing of a wide range of healthcare products. Their business segments include pharmaceuticals, medical devices, and consumer health products. Johnson & Johnson is known for their innovative approach in creating advanced treatments and solutions for various health conditions and diseases. With a focus on research and development, they strive to provide high-quality products that improve the well-being of people around the world. Johnson & Johnson's commitment to delivering value to their customers and stakeholders drives their success in the global healthcare industry.

Fair Value PRO

219.16 USD

Over-/Undervaluation PRO

16.0% undervalued

Expected Return

11.2 %

Sector

Health

Industry

Pharmaceuticals

Number of shares

2,429,400,000

Employees

134,500

Revenue per Employee

700,319.7 USD

Revenue growth Ø5 years

3.65 %

EBIT growth Ø5 years

9.72 %

Net Income growth Ø5 years

5.12 %

Website jnj.com

Country

United States 🇺🇸

Currency

USD

Initial public offering

Sep 25, 1944

ISIN

US4781601046

Sedol

2475833

Market capitalization

586.69 B USDMega Cap

Johnson & Johnson Directors Dealings

Quality Investing

8 / 10

Revenue growth (10Y) > 5%

Revenue growth (3Y) > 5 %

EBIT growth (10Y) > 5%

EBIT growth (3Y) > 5 %

Net debt < 4x EBIT

Profitable since 10Y+

EBIT Drawdown (10Y) < 50%

Return on Equity (ROE) > 15%

ROCE > 15%

Return Expectation > 10%

PEG

3.27

P/E ratio

21.13

P/Ee 2026

20.01

P/Ee 2027

18.44

P/Ee 2028

16.95

P/Ee 2029

15.6

P/Ee 2030

14.19

P/S

6.01

P/Se

5.58

EV/EBIT

19.06

P/B Ratio

7.19

ROE (Return on Equity)

32.87 %

ROA (Return on Assets)

13.46 %

ROCE (Return on Capital Employed)

40.23 %

ROIC (Return on Invested Capital)

20.7 %

Gross Margin

67.88 %

EBIT Margin

34.83 %

Net Margin

28.46 %

EPS (Earnings Per Share)

11.03 USD

Net Debt / EBIT

1.18

Debt/Equity

0.59

Dividend

5.14 USD

Dividend yield

2.2 %

Est. Dividend Yield

0.56 %

Payout Ratio

63.83 %

Dividend growth Ø5Y

4.17 %

Dividend payments per year

Dividend paid since

36 years

Dividend not reduced since

36 years

Dividend increased since

36 years

Dividend withholding tax

30 %

Last updated Jun 17, 2026, 5:59 AM

Johnson & Johnson Presentations

Johnson & Johnson Peer Group

Bristol-Myers Squibb Co

Johnson & Johnson Ticker

BERLIN · JNJ.BEDÜSSELDORF · JNJ.DUFRANKFURT · JNJ.FHAMBURG · JNJ.HMLONDON · 0R34.LMILAN · 1JNJ.MIMUNICH · JNJ.MUNEW YORK · JNJSIX · JNJUSD.SWSTUTTGART · JNJ.SGVIENNA · JNJ.VIXETRA · JNJ.DE

Johnson & Johnson FIGI

JNJ:US · BBG000BMHYD1JNJ:UA · BBG000BMHYP8JNJ:UC · BBG000BMHYZ7JNJ:UN · BBG000BMHZY5JNJ:UP · BBG000BMJ0L4JNJ:UB · BBG000BMJ1J5JNJ:UT · BBG000BMJ230JNJ:UM · BBG000BMJ2D9JNJ:UX · BBG000BMJ329JNJ:UD · BBG000BMJ4Y2JNJ:UF · BBG000BMJ720JNJ:VY · BBG000BMJ7H4

All fundamentals and in-depth analysis of Johnson & Johnson

Our stock analysis for Johnson & Johnson Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Johnson & Johnson Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Johnson & Johnson Revenue→

Johnson & Johnson Net Income→

Johnson & Johnson P/E→

Johnson & Johnson P/S→

Johnson & Johnson EBIT→

Johnson & Johnson Dividend→

Johnson & Johnson Directors Dealings→

Johnson & Johnson Stocks→

Johnson & Johnson Market capitalization→

Johnson & Johnson Debt→

Johnson & Johnson Liabilities→

Johnson & Johnson Equity→